ClinicalTrials.gg
CompletedNCT05027529ECMOsorbUpdated Feb 4, 2026

ECMOsorb Trial - Impact of a VA-ECMO in Combination With CytoSorb in Critically Ill Patients With Cardiogenic Shock

An interventional study of CytoSorb and VA-ECMO only in Cardiogenic Shock, sponsored by Christian Schulze. Completed at 1 site in Germany. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-02-04.

Sponsored by Christian Schulze · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 36 studies in Shock, Cardiogenic with a site in Germany — 13 open to participants now, 13 under way, none of them phase 3. Shock, Cardiogenic · Germany.

Enrollment
15th of 22
42 · median 60
Started
2021
the only one that year
No phase
13 of 36
4 open now
Registered
19th of 36
by date
Lead sponsor
1 of 36
Christian Schulze

Among the 36 studies in Shock, Cardiogenic with a site in Germany, this one is the 15th largest by enrollment of the 22 interventional ones that give a count, is the only one that started in 2021, is one of 13 with no phase, and was the 19th registered.

Shock, Cardiogenic

297 studies on the registry are indexed under Shock, Cardiogenic; 134 are open to participants now.

Browse Shock, Cardiogenic studies →

Open to participants now

13 of the 36 studies in Shock, Cardiogenic with a site in Germany are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 101 Shock, Cardiogenic studies recruiting now, 70 (69%) set no upper age limit and 9 (9%) stop at 75 or younger; 11 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Shock, Cardiogenic with a site in Germany, or all of them as a file.
02

Study summary

In the ECMOsorb study the impact of a veno-arterial -ECMO in combination with an extracorporeal cytokine hemadsorption system in critically ill patients with cardiogenic shock is to be examined

Read the detailed description

The prospective, interventional, randomised controlled and blinded ECMOsorb study investigates in critically ill patinets with cardiogenic shock and with veno-arterial ECMO (VA-ECMO) treatment the impact of an extracorporeal cytokin hemadsorption system on hemodynamics, defined by the Inotropic Score 72 hours after initiation of the adsorber (intervention) or normal ECMO tube (control) in the VA-ECMO.

03

Conditions studied

  • Cardiogenic Shock

Keywords

  • cardiogenic shock
  • VA-ECMO
  • venous arterial Extracorporeal Membrane Oxygenation
  • inotropic score
  • extracorporeal cytokine hemadsorption system
  • cytokine adsorber
  • intensive care
  • multi organ failure
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Cardiogenic shock of any cause and indication for VA-ECMO
  • Age between 18 and 80
  • Signed

Exclusion criteria

Exclusion Criteria:

  • Current participation in another interventional trial
  • Pregnancy
  • Current or immunomodulatory therapy
  • to VA-ECMO implantation.
  • Patients with pre - existing sepsis (raised CPR, positive PCT, leukozytosis, fever, positive blood cultures).
  • Shock duration> 12 h before evaluation.
  • Severe PVD (peripheral vessel disease) making ECMO-implantation impossible.
  • Aortic valve insufficiency / stenosis at least II °.
  • Age > 80 years.
  • CNS disease with fixed, dilated pupils (not drug-induced).
  • Severe concomitant disease with limited \<6 months.
  • CPR> 60min.
  • Shock due to other reasons
  • HIT positive (Heparin induced thrombocytopenia)
  • Very low counts (\< 20,000/µl)
  • Body weight less than 45 kg
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    VA-ECMO and CytoSorb

    standard ICU care WITH CytoSorb

    Device: CytoSorb

  • Placebo comparator
    VA-ECMO only

    standard ICU care WITHOUT CytoSorb

    Other: VA-ECMO only

Interventions

  • DeviceCytoSorb

    An extracorporeal cytokine hemoadsorption system is integrated in the VA-ECMO circuit

    Also known as: Standard ICU care (with VA-ECMO) AND CytoSorb Adsorber

  • OtherVA-ECMO only

    only VA-ECMO; NO extracorporeal cytokine hemoadsorption system is added

    Also known as: Standard ICU care (with VA-ECMO)

06

What researchers measure

Primary outcomes

  1. Change in inotropic score after 72h (difference between the two study groups)

    Inotropic Score: dopamine dose \[μg/kg/min\] + dobutamine dose \[μg/kg/min\] + 100x epinephrine dose \[μg/kg/min\] + 100x norepinephrine \[μg/kg/min\]

    Time frame: 72 hours

Secondary outcomes

  1. Interleukin 6

    pg/ml

    Time frame: 0 to 7 days after beginning of intervention

  2. Procalcitonin

    ng/ml

    Time frame: 0 to 7 days after beginning of intervention

  3. c-reactive protein

    mg/l

    Time frame: 0 to 7 days after beginning of intervention

  4. lactate

    mmol/l

    Time frame: 0 to 7 days after beginning of intervention

  5. creatinine

    µmol/l

    Time frame: 0 to 7 days after beginning of intervention

  6. glomerular filtration rate (GFR)

    ml/min

    Time frame: 0 to 7 days after beginning of intervention

  7. troponin

    pg/ml

    Time frame: 0 to 7 days after beginning of intervention

  8. creatinine kinase

    µmol/l\*s

    Time frame: 0 to 7 days after beginning of intervention

  9. myoglobine

    µg/l

    Time frame: 0 to 7 days after beginning of intervention

  10. urinary output

    ml/h

    Time frame: 0 to 7 days after beginning of intervention

  11. neuron specific enolase

    µg/l

    Time frame: 0 to 7 days after beginning of intervention

  12. s-100

    µg/l

    Time frame: 0 to 7 days after beginning of intervention

  13. cystatin c

    mg/l

    Time frame: 0 to 7 days after beginning of intervention

  14. galectin-3

    ng/ml

    Time frame: 0 to 7 days after beginning of intervention

  15. Duration of: renal replacement therapy (CVVHD), mechanical ventilation, ECMO therapy, inotropic /vasopressor treatment

    hours

    Time frame: day 30 after beginning of intervention

  16. 30 day, ICU and in-hospital mortality

    nominal scale (yes/no)

    Time frame: day 30 after beginning of intervention

  17. Length of stay in ICU and total length of hospital stay until discharge/transfer

    hours

    Time frame: day 30 after beginning of intervention

  18. Necessary Implantation of an Active Assist Device or heart transplantation

    nominal scale (yes/no)

    Time frame: day 30 after beginning of intervention

  19. SAPS II

    Simplified Acute Physiology Score II (Minimum value: 0 / maximum value: 163; higher values means worse outcome)

    Time frame: 0 to 7 days after beginning of intervention

  20. APACHE II score

    Acute Pysiology and Chronic Health Evaluation II (Minimum value: 0 / maximum value: 71; higher values means worse outcome)

    Time frame: 0 to 7 days after beginning of intervention

  21. SOFA score

    Sequential Organ Failure Assessment Score (Minimum value: 0 / maximum value: 24; higher value means worse outcome)

    Time frame: 0 to 7 days after beginning of intervention

  22. cerebreal performance category (CPC)

    CPC 1 (adequate function) to CPC 5 (brain dead)

    Time frame: 0 to 30 days after beginning of intervention

  23. Glasgow coma scale (GCS)

    Assessment scheme for disorders of consciousness and brain function (eyes, verbal, motor); scale from 3 (severe impairment) to 15 points (no abnormalities)

    Time frame: 0 to 30 days after beginning of intervention

  24. EuroQuol 5D-3L Descriptive System

    mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, and extreme problems.

    Time frame: 7 to 30 days after beginning of intervention

  25. EQ VAS

    EQ visual analogue scale (EQ VAS), patient's self-rated health on a vertical visual analogue scale where the endpoints are labelled 'Best imaginable health state' and 'Worst imaginable health state'.

    Time frame: 7 to 30 days after beginning of intervention

  26. Modified Rankin scale

    scale from 0 (no symptoms) to 6 (dead);

    Time frame: 0 to 30 days after beginning of intervention

  27. Measurement of right ventricular parameters

    measurements of right ventricular function in the echo (TAPSE in mm; FAC in %; RVEDD in mm; sPAP in mmHg; RA area in cm²; TASV in cm/s; ICV in mm)

    Time frame: 0 to 7 days after beginning of intervention

  28. Measurement of left ventricular parameters

    measurements of left ventricular function in the echo (LVEDD in mm; LVESD in mm; LVEF in %; VSD (yes/no); LVEDV in ml; LVESV in ml; GLS in %; LA volume in ml)

    Time frame: 0 to 7 days after beginning of intervention

  29. Measurement of kidney injury and kidney function

    NGAL, KIM-1, L-FABP, IGFBP7 in ng/ml

    Time frame: 0 to 7 days after beginning of intervention

  30. Interleukin 18

    pg/ml

    Time frame: 0 to 7 days after beginning of intervention

  31. incidence of apoplexy

    nominal scale (yes/no)

    Time frame: 30 days after beginning of intervention

  32. mean arterial pressure

    mmHg

    Time frame: 0 to 7 days after beginning of intervention

  33. central venous oxygen saturation

    in %

    Time frame: 0 to 7 days after beginning of intervention

  34. mixed venous oxygen saturation

    in %

    Time frame: 0 to 7 days after beginning of intervention

  35. arterial oxygen saturation

    in %

    Time frame: 0 to 7 days after beginning of intervention

  36. heart failure re-hospitalisation

    nominal scale (yes/no)

    Time frame: 30 days after beginning of intervention

  37. Brain natriuretic peptide (BNP)

    pg/ml

    Time frame: 0 to 7 days after beginning of intervention

  38. n-terminal pro brain natriuretic peptide (NT-proBNP)

    pg/ml

    Time frame: 0 to 7 days after beginning of intervention

07

Study locations

1 site
  • Jena University Hospital, Department of Cardiology
    Jena, Thuringia 07747, Germany
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2021 to primary completion in Dec 2025, 55 months.

Of 48 non-industry interventional studies with no phase under Shock, Cardiogenic, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 55. This study's 55 months is above that.

Counting every sponsor, half of 52 studies reached it within 39 months; a quarter within 24 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2021
First posted
Aug 30, 2021
StartActual
May 21, 2021
Primary completionActual
Dec 31, 2025
CompletionActual
Dec 31, 2025
Last update
Feb 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05027529
Lead sponsor
Christian Schulze
Responsible party
Christian Schulze (Prof. Dr. med., Jena University Hospital) — Sponsor-investigator
First posted
Aug 30, 2021
Start date
May 21, 2021
Primary completion
Dec 31, 2025
Completion
Dec 31, 2025
Last update
Feb 4, 2026

Study contacts

Christian Schulze, Prof.
study director · Jena University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion